CRP and spondyloarthropathy: Port et al. has shown that C1M, C3M, C4M, C6M, CRP, PRO-C4, and CPa9-HNE levels declined after 12 weeks in patients with spondyloarthritis treated with adalimumab compared with placebo [23], but on the contrary, this was not confirmed in another study with patients with spondyloarthritis 22 weeks after adalimumab treatment [22].